['soft tissue sarcoma']
['anlotinib', 'placebo']

        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Histological documentation of Soft Tissue Sarcoma,including Synovial
             sarcoma、Leiomyosarcoma、Alveolar soft part sarcoma、Undifferentiated pleomorphic
             sarcoma/malignant fibrous histiocytoma、Adipocytic Tumors、Fibrosarcoma、Clear cell
             sarcoma、Epithelioid sarcoma，With measurable disease.

          -  Within the past 6 months, using at least one failure of chemotherapy regimens
             (including anthracycline-based) in treating patients(except alveolar soft part
             sarcoma)

          -  18-70years,ECOG PS:0-1,Life expectancy of more than 3 months

          -  Main organs function is normal

          -  The woman patients of childbearing age who must agree to take contraceptive methods
             (e.g. intrauterine device, contraceptive pill or condom) during the research and
             within another 6 months after it; who are not in the lactation period and examined as
             negative in blood serum test or urine pregnancy test within 7 days before the
             research; The man patients who must agree to take contraceptive methods during the
             research and within another 6 months after it

        Exclusion Criteria:

          -  Prior treatment with Anlotinib

          -  With pleural effusion or ascites, cause respiratory syndrome

          -  Accepted the vascular endothelial growth inhibitor class targeted drug treatment of
             patients

          -  Plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the
             medicine-taking period of this research, including Cytotoxic Therapy, Signal
             Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks
             before taking the treatment with experimental drug); The patients who have already
             taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited
             Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping

          -  Symptoms of brain metastases cannot be controlled and treated within less than 2
             months

          -  With severe and failed to controlled diseases

          -  Occurred venous thromboembolic events within 6 months
      